IP Library Patent Application 17291667
Patent Application
App. No. 17/291,667

Use of oligodendrocytes from oral neuroectodermal stem cells in the repair of the nervous system

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/291,667
Abstract

This invention concerns a new method for differentiating oral neuroectodermal stem cells (CSO-NE), in particular human gingival neuroectodermal stem cells (CSGh), into oligodendrocytes (OL), and their use in the repair of the nervous system, in particular of head injuries.

Claims (16)

1 . A method for inducing differentiation of oral neuroectodermal stem cells into oligodendrocytes, said method comprising:

a) a step of differentiating said neuroectodermal oral stem cells into neuroepithelial stem cells in a neurogenic culture medium comprising DMEMf12, N 1 supplement, FGFb and EGF.

b) a step of differentiating the neuroepithelial stern cells obtained in step a) into neural stem cells in a neurogenic culture medium comprising DMEMf12, N1 supplement, Noggin protein, FGFb, retinoic acid and SHH factor.

c) a step of differentiating the neural stem cells obtained in step b) into oligodendrocyte pre-precursor cells in a neurogenic culture medium comprising DMEMf12, N1 supplement, B27 supplement and FGFb,

d) a step of differentiating the oligodendrocyte pre-precursor cells obtained in step c) into oligodendrocyte precursor cells in a neurogenic culture medium comprising

DMEMf12, PDGF-AA and SHH factor.

e) a step of differentiating oligodendrocyte precursor cells obtained in step d) into oligodendrocytes, and maturing said oligodendrocytes, in a neurogenic culture medium comprising DMEMf12, ICE-1 , biotin, CAMP, PDGF-AA, L-glutamine or Cilutamax™ and NT3.

2 . A method according to claim 1 , wherein the neuroectodemic oral stem cells are derived from gingival tissue.

3 . A cell population comprising oligodendrocytes obtained by the method according to claim 1 , said oligodendrocytes expressing the Msx1 gene.

4 . Cell population as defined in claim 3 , for use in cell therapy.

5 . Cell population for use according to claim 4 , for the treatment of head injuries.

6 . Culture medium for the differentiation of oral neuroectodermal stem cells into neuroepithelial stem cells comprising DMEMf12, N 1 supplement, FGFb and EGF.

7 . Culture medium for the differentiation of neuroepithelial stem cells into neural stem cells comprising DMFMf12, N1 supplement, Noggin protein, FGFb, retinoic acid and factor.

8 . Culture medium for the differentiation of neural stem cells into oligodendrocyte pre-precursor cells comprising DMFMf12, N1 supplement, B27 supplement and FGFb.

9 . Culture medium for the differentiation of oligodendrocyte pre-precursor cells into oligodendrocyte precursor cells comprising DMEMf12, PDGF-AA and SHH factor.

10 . Culture medium for the differentiation of oligodendrocyte precursor cells into oligodendrocytes, and for the maturation of said oligodendrocytes, comprising DMEMf12, IGF-1 biotin, CAMP, PDGF-AA, L-glutamine or Glutamax™ and NT3.

Assignments (3)
MERGER Recorded Aug 25, 2023
From: UNIVERSITE PARIS DIDEROT-PARIS 7; UNIVERSITE PARIS DESCARTES
To: UNIVERSITE DE PARIS
Reel/Frame 064702/0827 →
CHANGE OF NAME Recorded Aug 25, 2023
From: UNIVERSITE DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 064727/0194 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2021
From: FOURNIER, BENJAMIN; GOGLY, BRUNO; MARCHAND-LEROUX, CATHERINE; NASSIF, ALI; TAIHI, IHSENE
To: ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS; UNIVERSITÉ PARIS 5 RENÉ; UNIVERSITÉ PARIS DIDEROT - PARIS 7; UNIVERSITÉ PARIS EST - CRÉTEIL VAL DE MARNE
Reel/Frame 056743/0336 →